Stock Price & Analysis

Based on the provided data and recent developments, here's a concise analysis of TAK stock:

Technical Analysis The stock is currently trading at $13.50 in regular market hours with a slight decline of -0.22%. RSI at 56.58 indicates neutral momentum, while the MACD at 0.06 suggests a slightly bullish trend. The price is trading above its 20-day moving average of $13.21, indicating short-term upward momentum.

Recent Developments

• Leadership Transition: CEO Christophe Weber announced retirement effective June 2026, with Julie Kim set to succeed him
• Strong Financial Performance: 9.8% year-over-year revenue increase to ¥3528.2 billion for the nine months ending December 31, 2024
• Share Buyback Program: Announced ¥100 billion share buyback program
• Raised Guidance: Company upgraded its full-year outlook for FY2024

Market Sentiment The stock shows positive momentum based on:

• Improved core operating profit margins to 28.5%
• Strong product performance in Growth & Launch products
• Successful expansion in plasma-derived therapies
• Strategic leadership transition plan

Based on the technical indicators, recent positive developments, and improved financial outlook, TAK appears to be a buy at current levels. The stock shows stability with upside potential supported by strong fundamentals and strategic initiatives.

Based on recent earnings reports and technical analysis, TAK stock is projected to reach $15.50 by end of 2025, driven by strong revenue growth of 9.8% YoY and improved core operating profit margins reaching 28.5%. The company's strategic initiatives including JPY 100 billion share buyback program and new leadership transition under Julie Kim starting 2026 signals management's confidence in sustained growth trajectory. Technical indicators show the stock is currently trading near its fibonacci pivot point of $13.47 with upside resistance at $13.76, suggesting potential for further upward movement.

The S1 support level for TAK Stock is $13.24 ,The R1 resistant level for TAK Stock is $13.76.

As of the end of day on 2025-02-11, the price of TAK Stock was $13.44.

The target price for TAK Stock according to analyst rating is 14.80, with the highest price target at 14.80 and the lowest at 14.80. Analysts have a Moderate Buy rating on TAK Stock overall.

The market cap of TAK is $42.6B.

Based on the latest financial data and valuation metrics, TAK appears fairly valued at current levels. The company's P/E ratio has significantly improved from 22.8x to 11.17x in recent quarters, suggesting better earnings efficiency. TAK's EV/EBITDA of 9.05x in Q3 2025 indicates reasonable valuation compared to pharmaceutical industry averages. The company's strong revenue growth of 9.8% year-over-year and improved core operating profit margins to 28.5% demonstrate solid operational performance. Recent leadership transition announcement and raised FY2024 guidance, along with a new JPY 100B buyback program, reflect management's confidence in future growth. The company's attractive dividend yield of 4.56% provides additional value support for investors.

Takeda Pharmaceutical Company Limited is a Japan-based company mainly engaged in the pharmaceutical business. The Company is engaged in the research, development, manufacture and sale of pharmaceutical products, General medical products, quasi drugs and healthcare products in Japan and overseas. The Company's research and development functions are concentrated in four areas of oncology (cancer), digestive system diseases, rare diseases and neurology (neuropsychiatric diseases), as well as two business units of plasma fractionation products and vaccines. The Company is engaged in the improvement of pipelines at research and development centers located mainly in Japan and the United States.

Based on the provided data and recent earnings reports, here is the 2030 price prediction for TAK stock:

TAK stock is projected to reach $22-25 by 2030, driven by strong revenue growth in plasma-derived therapies and strategic pipeline developments. The company's successful leadership transition, operational efficiencies, and focus on Growth & Launch products which contributed 47% of total revenue support this bullish outlook. The expected biosimilar entry for ENTYVIO between 2030-2032 poses minimal near-term risk to this projection.

TAK has a total of 49281 employees.